spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Eloxatin 

 HSMN NewsFeed - 5 Sep 2018
Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 May 2013
A.P. Pharma Appoints New Management Team
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 18 Oct 2012
A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 9 Aug 2012
Hospira Announces U.S. Re-Launch Of Generic Oxaliplatin Injection
Biopharmaceuticals Generics Oncology
 HSMN NewsFeed - 31 Jul 2012
A.P. Pharma Appoints Robert Rosen to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Sep 2011
Theracrine Appoints Steven Kelly as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2010
BioVex Appoints Steven Kelly as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2010
APP Pharmaceuticals to Market Oxaliplatin Injection (Liquid) in the U.S.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Par Pharmaceutical Enters Into Agreement With sanofi-aventis to Settle Patent Litigation Over Generic Eloxatin(R)
Biopharmaceuticals Generics Oncology Litigation
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Apr 2010
Teva Settles Generic Eloxatin Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 25 Mar 2010
Teva Announces Tentative Approval of Generic Argatroban(R) Injection
Biopharmaceuticals Cardiology Generics FDA
 HSMN NewsFeed - 18 Mar 2010
Teva to Acquire ratiopharm
Biopharmaceuticals Generics Mergers & Acquisitions
 HSMN NewsFeed - 9 Mar 2010
Teva Announces the Appointment of Dr. Philip Frost as Chairman of Its Board of Directors
Biopharmaceuticals Generics Personnel
 HSMN NewsFeed - 2 Mar 2010
Teva Announces Favorable Court Ruling in Generic Hyzaar(R) and Cozaar(R) Litigation
Biopharmaceuticals Litigation Generics Cardiology
 HSMN NewsFeed - 25 Feb 2010
Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Feb 2010
Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
Biopharmaceuticals Litigation
 HSMN NewsFeed - 21 Jan 2010
Teva Announces Tentative Approval of Generic Femara(R) Tablets
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 7 Jan 2010
Teva Announces Settlement Agreements with AstraZeneca Regarding Generic Prilosec(R) and Nexium(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 21 Dec 2009
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 10 Nov 2009
Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
Biopharmaceuticals Generics Drug Delivery Litigation
 HSMN NewsFeed - 11 Aug 2009
Teva Announces Approval and Launch of Oxaliplatin Injection
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 11 Aug 2009
Hospira Launches Generic Oxaliplatin Injection
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 18 Jun 2009
Hospira Receives Favorable Court Decision on Eloxatin(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 19 Feb 2009
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Biopharmaceuticals Licensing
 HSMN NewsFeed - 22 Oct 2008
Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Sep 2008
Access Pharmaceuticals Retains Piper Jaffray to Augment Strategic Partnering Efforts
Biopharmaceuticals
 HSMN NewsFeed - 10 Jul 2008
Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 May 2008
New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2008
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jan 2008
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Biopharmaceuticals Generics
 HSMN NewsFeed - 7 Jan 2008
Access Pharmaceuticals Closes Acquisition of Somanta Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Dec 2007
Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2007
Access Pharmaceuticals Announces $19.5 Million Recapitalization
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Health Canada approves new chemotherapy treatment for patients with metastatic colorectal cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2007
Eloxatin(R) (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2007
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Feb 2007
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Conditions
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 29

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 29 additional stories matching:
Eloxatin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.